The treatment of systemic candidiasis in neonates with oral fluconazole

Annals of Tropical Paediatrics

Volumn 17, Issue 3, 1997, Pages 263-271

  Driessen, Marie ^a,b   Ellis, Jeff B ^a   Muwazi, Faith ^a   De Villiers, François P R ^a  

^a Ga Rankuwa Hospital   (South Africa)

^b NONE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ARTICLE; BLOOD CULTURE; CANDIDIASIS; CLINICAL ARTICLE; DRUG EFFICACY; FUNGUS CULTURE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; NEWBORN; NEWBORN INFECTION; ORAL DRUG ADMINISTRATION; RELAPSE; SEPTICEMIA; SOUTH AFRICA; TIME; TREATMENT OUTCOME;

EID: 0030799186     PISSN: 02724936     EISSN: None     Source Type: Journal    
DOI: 10.1080/02724936.1997.11747897     Document Type: Article

References (43)

1. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics 1984; 73:144-52.
2. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics 1984; 73:153-7.
3. Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low-birth-weight infant. Pediatrics 1986; 78: 225-32.
4. Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am 1988; 35:543-63.
5. Faix RG, Kovarik SM, Shaw TB, Johnson RV. Mucocutaneous and invasive candidiasis among very low-birth-weight (< 1500gram) infants in intensive care nurseries: a progressive study. Pediatrics 1989; 83:101-7.
6. Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984; 105:616-22.
7. Johnson DE, Thompson TR, Green TP, Ferreiri P. Systemic candidiasis in very low-birth-weight infants (<1500 g). Pediatrics 1984; 73:138-43.
8. Smith H, Congdon P. Neonatal systemic candidiasis. Arch Dis Child 1985; 60:365-9.
9. Weese-Mayer DE, Fondriest DW, Brouillette RT, Schulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case control study. Pediatr Infect Dis J 1987; 6:190-6.
10. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9:51-6.
11. Drouhet E, Dupont B. Evaluation of antifungal agents: past, present, and future. Rev Infect Dis 1987; 9:5-14.
12. Miller RP, Bates JH. Amphotericin B toxicity: a follow up report of 53 patients. Ann Intern Med 1969; 71:1089-95.
13. Bennett JE. Flucytosine. Ann Intern Med 1977; 86:319-22.
14. Dismukes WE. Azole antifungal drugs: old and new. Ann Intern Med 1988; 109:177-9.
15. Marriott MS, Richardson K. The discovery and mode of action of fluconazole. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Paris: Proust, 1987; 81-92.
16. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988; 1:187-217.
17. Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ. Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 1990; 12(Suppl. 3): S267-71.
18. Viscoli C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragna A. Fluconazole in the treatment of Candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991; 35:365-7.
19. Bunin N. Oral fluconazole for treatment of disseminated fungal infection. Pediatr Infect Dis J 1989; 8:62.
20. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animal and humans. Antimicrob Agents Chemother 1985; 28:648-53.
21. Graybill JR. New antifungal agents. Eur J Clin Microbiol Infect Dis 1989; 8:402-12.
22. Hanger DP, Jevons S, Shaw JTB. Fluconazole and testosterone: in vivo and in vitro studies. Antimicrob Agents Chemother 1988; 32:646-8.
23. Hay RJ. The azole antifungal drugs. J Antimicrob Chemother 1987; 20:1-3.
24. Brammer KF, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(Suppl. 3):S318-26.
25. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990; 12(Suppl. 3):S349-63.
26. Viscoli C, Castagnola E, Corsini M, Gastaldi R, Soliani M, Terragna A. Fluconazole therapy in an underweight infant. Eur J Clin Microbiol Infect Dis 1989; 8:925.
27. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989; 12:239S-47S.
28. Diamond RD, Saunders C, Sugar AM. Fluconazole therapy of serious Candida infections. Abstracts of the Tenth Congress of the International Society of Human and Animal Mycology. June 1988, Barcelona. In: Fluconazole. Abstracts from the World Literature. Langhorne, PA: ADIS Press International, 1988.
29. Arndt CAS, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplac DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157:178-80.
30. Foulds G, Wajszczuk C, Weidler DJ, Garg DC, Gibson P. Steady state parenteral kinetics of fluconazole in man. In: Fluconazole. Abstracts from the World Literature. Langhorne, PA: ADIS Press International, 1998.
31. Foulds G, Brennam DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28:363-6.
32. Brammer KW, Tarbit MH. A review of the pharmacokinetics of fluconazole (UK-49, 858) in laboratory animals and man. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Paris: Proust, 1987; 141-9.
33. Troke PF. Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infection. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Paris: Proust: 1987; 103-12.
34. Van't Wout JW, Mattie H, Van Furth R. A prospective study of the efficacy of fluconazole (UK-49, 858) against deep-seated fungal infections. J Antimicrob Chemother 1988; 21:665-72.
35. Brammer KW, Farrow PR, Feczko JM. Fluconazole, a new systemically effective antifungal agent, for use in hospitalized patients. In: Fluconazole. Abstracts from the World Literature. Langhorne, PA: ADIS Press International, 1988.
36. Yagupsky P, Dagan R, Chipman M, et al. Pseudo outbreak of Candida guilliermondii fungemia in a neonatal intensive care unit. Pediatr Infect Dis J 1991; 10:928-32.
37. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 1989; 8:99-104.
38. Dato V, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990; 9:309-14.
39. Badenhorst L, Botha PL, Janse van Rensburg MN. The incidence of hospital fungal infections - yeast fungemia. S Afr Med J 1991; 79:302-3.
40. Krzeska I, Yeates RA, Pfaff G. Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs Exp Clin Res 1993; XIX:267-71.
41. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh T. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120:987-93.
42. Bode S, Pedersen-Bjergaard L, Hjelt K. Candida albicans septicemia in a premature infant successfully treated with oral fluconazole. Scand J Infect Dis 1992; 24:673-5.
43. Epelbaum S, Laurent C, Morin G, Berquin P, Puissan C. Failure of fluconazole treatment in Candida meningitis. J Pediatr 1993; 123:168-9.